Tested Applications
| Positive WB detected in | HepG2 cells, BxPC-3 cells, HeLa cells |
| Positive IHC detected in | human colon tissue, human breast cancer tissue, human brown disease, human cervical cancer tissue, human liver cancer tissue, human lung cancer tissue, human thyroid cancer tissue, mouse colon tissue, rat colon tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF-Fro detected in | mouse liver tissue |
| Positive IF/ICC detected in | HeLa cells, A431 cells |
| Positive FC (Intra) detected in | MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunohistochemistry (IHC) | IHC : 1:150-1:600 |
| Immunofluorescence (IF)-FRO | IF-FRO : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
14965-1-AP targets Cytokeratin 19 in WB, IHC, IF/ICC, IF-Fro, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat, monkey |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag6830 Product name: Recombinant human KRT19 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-400 aa of BC002539 Sequence: MTSYSYRQSSATSSFGGLGGGSVRFGPGVAFRAPSIHGGSGGRGVSVSSARFVSSSSSGGYGGGYGGVLTASDGLLAGNEKLTMQNLNDRLASYLDKVRALEAANGELEVKIRDWYQKQGPGPSRDYSHYYTTIQDLRDKILGATIENSRIVLQIDNARLAADDFRTKFETEQALRMSVEADINGLRRVLDELTLARTDLEMQIEGLKEELAYLKKNHEEEISTLRGQVGGQVSVEVDSAPGTDLAKILSDMRSQYEVMAEQNRKDAEAWFTSRTEELNREVAGHTEQLQMSRSEVTDLRRTLQGLEIELQSQLSMKAALEDTLAETEARFGAQLAHIQALISGIEAQLGDVRADSERQNQEYQRLMDIKSRLEQEIATYRSLLEGQEDHYNNLSASKVL Predict reactive species |
| Full Name | keratin 19 |
| Calculated Molecular Weight | 44 kDa |
| Observed Molecular Weight | 40 kDa, 46 kDa |
| GenBank Accession Number | BC002539 |
| Gene Symbol | Cytokeratin 19 |
| Gene ID (NCBI) | 3880 |
| RRID | AB_2133324 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P08727 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Cytokeratin 19 (CK19 or KRT19) is a type I (acidic) cytokeratin. It is an intermediate filament protein providing structural rigidity and multipurpose scaffolds in epithelial cells. CK19 is often overexpressed in various cancers (e.g., hepatocellular carcinoma [HCC], pancreatic adenocarcinoma, lung cancer) and serves as a biomarker for hepatic progenitor cells (HPCs) associated with poor prognosis in HCC patients . Additionally, CK19 expression is common in pancreatic and gastrointestinal adenocarcinomasand has been studied as a potential diagnostic and prognostic marker for pancreatic neuroendocrine tumors (PNETs), where positive CK19 expression correlates with poor prognosis. Serum CK19 fragments (e.g., CYFRA 21-1, CK19-2G2) have been investigated as tumor markers for lung and breast cancer, with preoperative levels associated with metastasis and survival. This antibody, generated against full length KRT19 protein, also recognizes KRT17, another type I keratin homologous to KRT19.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for Cytokeratin 19 antibody 14965-1-AP | Download protocol |
| IF protocol for Cytokeratin 19 antibody 14965-1-AP | Download protocol |
| IHC protocol for Cytokeratin 19 antibody 14965-1-AP | Download protocol |
| WB protocol for Cytokeratin 19 antibody 14965-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The Cytokeratin 19 (KRT19) Polyclonal antibody (Cat# 14965-1-AP) has accumulated 24 citations published in journals including Nature, Gastroenterology, Hepatology, Cell Reports, PLoS Biology, Molecular Medicine, and Nature Communications. The research fields covered include liver fibrosis, cholestasis, hepatocellular carcinoma, pancreatic cancer, biliary duct biology, organoid differentiation, and metabolic regulation. Cited applications include IHC, IF, and WB across human, mouse, rat, and monkey species.
| Species | Application | Title |
|---|---|---|
Gastroenterology ECM1 Prevents Activation of Transforming Growth Factor β, Hepatic Stellate Cells, and Fibrogenesis in Mice. | ||
Cancer Res DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. | ||
Int J Biol Sci Hepatobiliary organoids differentiated from hiPSCs relieve cholestasis-induced liver fibrosis in nonhuman primates | ||
Arch Toxicol Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model. |
Reviews
What customers say
Both reviewers gave this antibody a perfect 5-star rating using lot 00048024 at a 1:1000 dilution. One user tested it in Western Blot and Immunofluorescence, noting that "CYTOKERATIN works very good." The other validated it across Western Blot, Immunohistochemistry, and Immunofluorescence, describing it as "wonderful antibodies, easy to use." Overall, users report strong performance and ease of use across multiple applications with consistent results.
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
Sai Sindhura (Verified Customer) (01-08-2026) | CYTOKERATIN works very good
|
Mounika (Verified Customer) (01-08-2026) | Wonderful antibodies, easy to use, Happy!
|
